Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeutics, supported by Premier Miton. The funding will accelerate their transition into a clinical-stage RNA therapeutics business.
Amount Raised
€3.1 Million
Round Type
Seed
Greater LondonBiotechnologyHealth CareTherapeuticsInvestors
Description
Thalia Therapeutics, a British BioTech company, has announced the acquisition of Sanmirna Therapeutics alongside a €3.1 million funding round. The round was supported by new and existing investors, including Premier Miton. This deal aims to enhance Thalia's oncology pipeline and diversify its RNA therapeutics offerings. The funding will help bring a clinical-stage microRNA therapeutic candidate for Acute Myeloid Leukaemia into their portfolio.
Quick answer
Thalia Therapeutics plc raised €3.1 Million in a Seed round, dated June 26, 2026. Investors: Premier Miton. Thalia Therapeutics plc is based in Greater London, England, United Kingdom.
- How much did Thalia Therapeutics plc raise?
- Thalia Therapeutics plc raised €3.1 Million in a Seed round on June 26, 2026.
- Who invested in Thalia Therapeutics plc?
- Premier Miton is named as investors in this round.
- What does Thalia Therapeutics plc do?
- Thalia Therapeutics plc is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease.
- Where is Thalia Therapeutics plc based and how big is it?
- Thalia Therapeutics plc is based in Greater London, England, United Kingdom.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Thalia Therapeutics plc that raised within 45 days of this round, from Fundz verified event records.
- Avere Therapeutics raised $500M (Post-IPO Equity) on August 10, 2026.
- Epicrispr Biotechnologies raised $90M (Series C) on August 10, 2026.
- Hopstem Biotechnology raised an undisclosed amount (Series C) on August 10, 2026.
- Os Therapies raised $5M on August 10, 2026.
- Opal Therapeutics raised $1.3M (Grant) on August 7, 2026.
- Tarsus Pharmaceuticals raised $125M (Post-IPO Equity) on August 6, 2026.
Who to call at Thalia Therapeutics plc, and when
A new round usually means Thalia Therapeutics plc is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Thalia Therapeutics plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Thalia Therapeutics plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Thalia Therapeutics plc. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Thalia Therapeutics plc raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Thalia Therapeutics plc raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.